Liu Liu1, Yangyang Wang1, Xiaoyan Chen2, Yichao Tian1, Tin Chiu Li2, Lijuan Zhao1, Qiaoqiao Chen1, Mingling Wei1, Songying Zhang3. 1. Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3# Qingchun East Road, Hangzhou, 310016, People's Republic of China. 2. Assisted Conception Unit, Department of Obstetrics & Gynecology, Chinese University of Hong Kong, Hong Kong SAR, China. 3. Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province Assisted Reproduction Unit, Department of Obstetrics and Gynecology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3# Qingchun East Road, Hangzhou, 310016, People's Republic of China. zhangsongying@zju.edu.cn.
Abstract
PURPOSE: To examine the expression of MUC16 in the endometrium peri-implantation period in three different cohort studies. METHODS: This was a retrospective observational cohort study. A total of 245 participants were recruited in three separate cohort studies: (1) women with recurrent miscarriage (n = 50) and fertile controls (n = 29); (2) women who had high (n = 20) or normal (n = 20) progesterone on the day of hCG trigger in ovarian stimulation cycle for IVF; and (3) women who did (n = 95) or did not (n = 31) conceive following frozen embryo transfer in HRT cycles. All subjects had archived endometrial samples precisely taken on LH+7 in natural cycles, or hCG+6 in ovarian stimulation cycles, or P+5 in HRT cycles. The H-score (median, range) of MUC16 in the luminal epithelium and glandular epithelium was determined by using immunohistochemistry. RESULTS: The median (range) of H-score of MUC16 in the luminal epithelium (1) in women with recurrent pregnancy loss was 23.7 (0-300), which was significantly (P < 0.05) lower than that of 118.4 (7.7-300) in fertile controls; (2) in women with elevated progesterone on the day of hCG administration (147.8, 18.0-230.1), significantly (P < 0.05) higher than that of women with normal progesterone (61.0, 2.3-205.3); (3) in women who conceived (23.1, 0-250.3), significantly (P < 0.001) lower than that in women who did not conceive (58.4, 0-300). CONCLUSION: The expression of MUC16 in all three cohort studies is consistent with it being an inhibitor of implantation.
PURPOSE: To examine the expression of MUC16 in the endometrium peri-implantation period in three different cohort studies. METHODS: This was a retrospective observational cohort study. A total of 245 participants were recruited in three separate cohort studies: (1) women with recurrent miscarriage (n = 50) and fertile controls (n = 29); (2) women who had high (n = 20) or normal (n = 20) progesterone on the day of hCG trigger in ovarian stimulation cycle for IVF; and (3) women who did (n = 95) or did not (n = 31) conceive following frozen embryo transfer in HRT cycles. All subjects had archived endometrial samples precisely taken on LH+7 in natural cycles, or hCG+6 in ovarian stimulation cycles, or P+5 in HRT cycles. The H-score (median, range) of MUC16 in the luminal epithelium and glandular epithelium was determined by using immunohistochemistry. RESULTS: The median (range) of H-score of MUC16 in the luminal epithelium (1) in women with recurrent pregnancy loss was 23.7 (0-300), which was significantly (P < 0.05) lower than that of 118.4 (7.7-300) in fertile controls; (2) in women with elevated progesterone on the day of hCG administration (147.8, 18.0-230.1), significantly (P < 0.05) higher than that of women with normal progesterone (61.0, 2.3-205.3); (3) in women who conceived (23.1, 0-250.3), significantly (P < 0.001) lower than that in women who did not conceive (58.4, 0-300). CONCLUSION: The expression of MUC16 in all three cohort studies is consistent with it being an inhibitor of implantation.
Authors: X Y Jin; L J Zhao; D H Luo; L Liu; Y D Dai; X X Hu; Y Y Wang; X Lin; F Hong; T C Li; S Y Zhang Journal: Hum Reprod Date: 2017-12-01 Impact factor: 6.918